Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Ipatasertib|DRUG: Paclitaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: Queen Mary University of London
Collaborators: Westdeutsche Studiengruppe GmbH (WSG)|MedSIR|Hoffmann-La Roche